A nuclear beacon of hope: an advanced, metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE
, 1, 1, 1, 1
Abstract
Glucagonoma is a rare pancreatic neuroendocrine tumor (panNET) that can be characterized by increased secretion of glucagon and distinguishing symptoms — glucagonoma syndrome with a typical dermatosis, necrolytic migratory erythema, being its most common manifestation. While surgery and somatostatin analogs remain first-line therapeutic options in panNETs, radioligand therapy with [177Lu]Lu-DOTA-TATE is a recommended second-line palliative treatment in advanced, metastatic cases. However, its prospects and efficacy are still not vastly researched in less frequent neuroendocrine neoplasms. Here, we present an extraordinary case of a metastatic glucagonoma treated with [177Lu]Lu-DOTA-TATE used as a second-line treatment in progressive disease.
Keywords: glucagonomapancreatic neuroendocrine tumorradioligand therapy[177Lu]Lu-DOTA-TATElutetiumnecrolytic migratory erythema
References
- Qu Y, Li H, Wang X, et al. Clinical characteristics and management of functional pancreatic neuroendocrine neoplasms: a single institution 20-year experience with 286 patients. Int J Endocrinol. 2020: 1030518.
- Zandee WT, Brabander T, Blažević A, et al. Symptomatic and radiological response to 177lu-dotatate for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2019; 104(4): 1336–1344.
- Mavi ME, Tuncel M. Treatment of glucagonoma-related necrolytic migratory erythema with peptide receptor radionuclide therapy. Clin Nucl Med. 2021; 46(12): 1002–1003.
- Pavel M, Öberg K, Falconi M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7): 844–860.
